Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted an opinion and recommended granting marketing authorization for Kisqali for the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, at high risk of disease recurrence, including those with node-negative disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Election 2024: Where To Put Your Money Ahead of the Vote
- On drug prices, Harris pushes for cuts, Trump offers few specifics, NYTimes say
- LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street’s “Strong Buy” Rating?
- Trump backs off support of controversial drug pricing plan, STAT reports
- Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher